- Homeopathy, returning brands shape pain relief
- Egalet, Shionogi to develop abuse-deterrent opioids
- New York's online database of drug prescriptions curtailing 'doctor shopping'
- FDA issues sweeping new requirements for long-acting opioids
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
NEWARK, Calif. — Depomed has launched a new drug for breakthrough pain in cancer patients, the company said Monday.
The drug maker announced the launch of Lazanda (fentanyl) nasal spray, meant for treating adults who are taking opioid painkillers, but have become tolerant to them. The company also have launched a Signature Support Program designed to streamline patient access to the drug, including reimbursement and co-pay assistance. Other benefits of the program include prescription reminders and eligibility for one month's supply for free.
"Breakthrough pain is very common among cancer patients and can be properly managed to reduce the number and severity of episodes and the interference of daily activities," University of Arizona anesthesiology professor Emil Annabi said. "Studies show that breakthrough pain is associated with poorer function and higher cost of care, which is why cancer patients need support services so they can focus on getting pain relief and not be troubled by reimbursement and access issues."